Uptake and Impact of Carrier Testing for Cystic Fibrosis

Publisher： Karger

E-ISSN： 1662-8063|1|1|23-35

ISSN： 1662-4246

Source： Public Health Genomics, Vol.1, Iss.1, 1998-05, pp. : 23-35

Disclaimer: Any content in publications that violate the sovereignty, the constitution or regulations of the PRC is not accepted or approved by CNPIEC.

Previous Menu Next

Abstract

Related content

Carrier Testing Program in a High-Risk Cystic Fibrosis Population from Northeastern Italy

By  

Public Health Genomics, Vol. 2, Iss. 2-3, 2000-03 ,pp. : 82-90

Karger

Access to resources Recommend Favorite

Is Cystic Fibrosis Carrier Screening Cost Effective?

By  

Public Health Genomics, Vol. 10, Iss. 2, 2007-03 ,pp. : 103-109

Karger

Access to resources Recommend Favorite

A Commentary on the NIH Consensus Development Statement ‘Genetic Testing for Cystic Fibrosis’

By  

Public Health Genomics, Vol. 1, Iss. 1, 1998-05 ,pp. : 53-56

Karger

Access to resources Recommend Favorite

Assessing the Potential Success of Cystic Fibrosis Carrier Screening: Lessons Learned from Tay-Sachs Disease and β-Thalassemia

By  

Public Health Genomics, Vol. 13, Iss. 5, 2009-10 ,pp. : 310-319

Karger

Access to resources Recommend Favorite

How Should Preconceptional Cystic Fibrosis Carrier Screening Be Provided? Opinions of Potential Providers and the Target Population

By  

Public Health Genomics, Vol. 6, Iss. 3, 2004-06 ,pp. : 157-165

Karger

Access to resources Recommend Favorite